1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 20, 2001
---------------------------------
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-18231 84-1043826
---------------------------- --------------------- ---------------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer Identification No.)
of Incorporation)
2579 Midpoint Drive, Fort Collins, Colorado 80525
------------------------------------------------------------
(Address of principal executive offices, including zip code)
(970) 482-5868
------------------------------------------------------------
(Registrant's telephone number, including area code)
2
Item 5. Other Events.
Atrix Laboratories, Inc. (the "Company") announced today that it has
settled the first of three licensing disputes with Block Drug, a wholly owned
subsidiary of GlaxoSmithKline submitted last year. The settlement resolves a
pricing dispute over Block's sale of the Company's periodontal product,
Atridox(R) and provides payment owed to the Company for the sale of the product.
As part of the settlement, the Company received payment owed for product sales
in 1999. In addition, the Company implemented a new pricing schedule for future
purchases in an effort to resolve issues of this type in the future. The Company
intends to pursue resolution of the remaining legal issues with Block, including
Block's failure to pay the Company certain milestones following approval by the
U.S. Food and Drug Administration of Atrisorb-D(R) guided tissue regeneration
barrier product.
The text of Press Release is attached hereto as Exhibit 99.1.
Item 7. Exhibits.
99.1 Text of Press Release dated April 24, 2001.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ATRIX LABORATORIES, INC.
By: /s/ Brian G. Richmond
----------------------------------
Brian G. Richmond
Chief Financial Officer
Date: April 24, 2001
4
EXHIBIT INDEX
Exhibit Description
------- -----------
99.1 Text of Press Release dated April 24, 2001.